Resveratrol as anti-aging therapy for age-related bone loss

Rejuvenation Research

Volumn 17, Issue 5, 2014, Pages 439-445

  Fernández Tresguerres, Isabel ^a   Tamimi, Faleh ^b   Eimar, Hazem ^b   Barralet, Jake ^b   Torres, Jesús ^a   Blanco, Luis ^a   Tresguerres, Jesús A F ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; RESVERATROL; BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; BONE MASS; CONTROLLED STUDY; DRUG EFFECT; FEMUR; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; PROTEIN BLOOD LEVEL; RAT; RIGIDITY; AGING; ANIMAL; BIOMECHANICS; BLOOD; BODY WEIGHT; DRUG EFFECTS; DRUG THERAPY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOGRAPHY; REJUVENATION; WISTAR RAT;

AGING; ANIMALS; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; BODY WEIGHT; BONE RESORPTION; COLLAGEN TYPE I; FEMUR; MALE; ORGAN SIZE; OSTEOCALCIN; PEPTIDES; RATS, WISTAR; REJUVENATION; STILBENES; X-RAY MICROTOMOGRAPHY;

EID: 84911994007     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2014.1551     Document Type: Article

References (61)

1. Sommerfeldt DW, Rubin CT. Biology of bone and how it orchestrates the form and function of the skeleton. Eur Spine J 2001;10:S86-S95.
2. Raisz LG, Seeman E. Causes of age-related bone loss and bone fragility: An alternative view. J Bone Miner Res 2001;16:1948-1952.
3. Inderjeeth CA, Foo ACH, Lai MMY, Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence. Bone 2009;44:744-751.
4. Vivalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol 2006;11:217-225.
5. Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, Prins JB, Martin JH. Resveratrol-pills to replace a healthy diet? Br J Clin Pharmacol 2011;72:27-38.
6. Fremont L. Biological effects of resveratrol. Life Sci 2000;66:663-673.
7. Farris P, Krutmann J, Li YH, McDaniel D, Krol Y. Resveratrol: A unique antioxidant offering a multi-mechanistic approach for treating aging skin. J Drugs Dermatol 2013;12:1389-1394.
8. Sung MM, Dyck JR. Age-related cardiovascular disease and the beneficial effects of calorie restriction. Heart Fail Rev 2012;17:707-719.
9. Duntas LH. Resveratrol and its impact on aging and thyroid function. J Endocrinol Invest 2011;34:788-792.
10. Mobasheri A, Shakibaei M. Osteogenic effects of resveratrol in vitro: Potential for the prevention and treatment of osteoporosis. Ann NY Acad Sci 2013;1290:59-66.
11. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1998;30;253:859-863.
12. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T. Delaisse JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005;65:9943-9952.
13. Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 2011;1;286:11492-11505.
14. Shakibaei M, Shayan P, Busch F, Aldinger C, Buhrmann C, Lueders C, Mobasheri A. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells: Potential role of Runx2 deacetylation. PLoS One 2012;7:e35712.
15. He X, Andersson G, Lindgren U, Li Y. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun 2010;22;401:356-362.
16. Liu ZP, Li WX, Yu B, Huang J, Sun J, Huo JS, Liu CX. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J Med Food 2005;8:14-19.
17. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol 2000;46:78-83.
18. Zhao H, Li X, Li N, Liu T, Liu J, Li Z, Xiao H, Li J. Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus. Br J Nutr 2013;30:1-11.
19. Habold C, Momken I, Ouadi A, Bekaert V, Brasse D. Effect of prior treatment with resveratrol on density and structure of rat long bones after tail-suspension. J Bone Miner Res 2011;29:15-22.
20. Durbin SM, Jackson JR, Ryan MJ, Gigliotti JC, Always SE, Toy JC. Resveratrol supplementation preserves long bone mass, microstructure, and strength in hindlimb-suspended old male rats. J Bone Miner Res 2014;32:38-47.
21. Quinn R. Comparing rat's to human age: How old is my rat in people years? Nutrition 2005;21:775-777.
22. Chen H, Zhou X, Emura S, Shoumura S. Site-specific bone loss in senescence-accelerated mouse (SAMP6): A murine model for senile osteoporosis. Exp Gerontol 2009;44:792-798.
23. Garnero P. Biomarkers for osteoporosis management: Utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther 2008;12:157-170.
24. Barou O, Valentin D, Vico L, Tirode C, Barbier A, Alexandre C, Lafage-Proust MH. High-resolution three-dimensional micro-computed tomography detects bone loss and changes in trabecular architecture early: Comparison with DEXA and bone histomorphometry in a rat model of disuse osteoporosis. Invest Radiol 2002;37:40-42.
25. Duque G, Huang DC, Dion N, Macoritto M, Rivas D, Li W, Yang XF, Li J, Lian J, Marino FT, Barralet J, Lascau V, Deschênes C, Ste-Marie LG, Kremer R. Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res 2011;26:1472-1483.
26. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Müller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010;25:1468-1486.
27. Chappard D, Palle S, Alexandre C, Vico L, Riffat G. Bone embedding in pure methyl-methacrylate at low-temperature preserves enzyme-activities. Acta Histochem 1987;81:183-190.
28. Jarvinen TLN, Sievanen H, Jokihaara J, Einhorn TA. Revival of bone strength: The bottom line. J Bone Miner Res 2005;20:717-720.
29. Borah B, Gross GJ, Dufresne TE, Smith TS, Cockman MD, Chmielewski PA, Lundy MW, Hartke JR, Sod EW. Three-dimensional micro-imaging (MRmicrol and micro-CT), finite element modeling, and rapid prototyping provide unique insights into bone architecture in osteoporosis. Anat Rec 2001;265:101-110.
30. Blasiak J, Glowaki S, Kauppinen A, Kaarniranta K. Mitochondrial and nuclear DNA damage and repair in age-related macular degeneration. Int J Mol Sci 2013;14:2996-3010.
31. Kireev RA, Tresguerres ACF, Garcia C, Ariznavarreta C, Vara E, Tresguerres JAF. Melatonin is able to prevent the liver of old castrated female rats from oxidative and proinflammatory damage. J Pineal Res 2008;45:394-402.
32. Cuesta S, Kireev RA, Forman K, Garcia C, Escames G, Ariznavarreta C, Vara E, Tresguerres JAF. Melatonin improves inflammation processes in liver of senescence- accelerated prone male mice (SAMP8). Exp Gerontol 2010;45:950-958.
33. Forman K, Vara E, Garcia C, Kireev RA, Cuesta S, Acuña-Castroviejo D, Tresguerres JAF. Effect of melatonin treatment on the cardiological alterations in a murine model of accelerated aging. J Pineal Res 2010;49:312-320.
34. Acuña-Castroviejo D, Carretero M, Doerrier C, Lopez LC, Garcia Corzo L, Tresguerres JAF, Escames. Melatonin protects lung mitochondria from aging. Age 2012;34:681-692.
35. Cuesta S, Kireev RA, Forman K, Garcia C, Escames G, Vara E, Tresguerres JAF. Beneficial effect of melatonin treatment on inflammation, apoptosis and oxidative stress on the pancreas of senescence accelerated mice model. Mech Ageing Dev 2011;132:573-582.
36. Tresguerres IF, Tamimi F, Eimar H, Barralet J, Prieto S, Torres J, Calvo-Guirado JL, Fernández-Tresguerres JA. Melatonin dietary supplement as anti-aging therapy for age-related bone loss. Rejuvenation Res 2014;11.
37. Rahman K. Studies on free radicals, antioxidants, and cofactors. Clin Interv Aging 2007;2:219-236.
38. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol 2010;31:400-419.
39. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010;54:7-16.
40. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009;47:2170-2182.
41. Dawn B. Resveratrol: Ready for prime time? J Mol Cell Cardiol 2007;42:484-486.
42. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;16;444:337-342.
43. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8:157-168.
44. Juric D, Wojciechowski P, Das DK, Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 2007;292:H2138-H2143.
45. Gurusamy N, Lekli I, Mukherjee S, Ray D, Ahsan MK, Gherghiceanu M, Popescu LM, Das DK. Cardioprotection by resveratrol: A novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res 2010;1;86:103-112.
46. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009;54:668-675.
47. Zhang Y, Luo Z, Ma L, Xu Q, Yang Q, Si L. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med 2010;25:729-734.
48. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: An intensive review. Am J Health Syst Pharm 2004;15;61:160-173.
49. Gloire G, Dejardin E, Piette J. Extending the nuclear roles of IkappaB kinase subunits. Biochem Pharmacol 2006;30;72:1081-1089.
50. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288.
51. Helenius M, Kyrylenko S, Vehviläinen P, Salminen A. Characterization of aging-associated up-regulation of constitutive nuclear factor-kappa B binding activity. Antioxid Redox Signal 2001;3:147-156.
52. Sadruddin S, Arora R. Resveratrol: Biologic and therapeutic implications. J Cardiometab Syndr 2009;4:102-106.
53. Mosekilde L. Age-related changes in bone mass, structure, and strength - effects of loading. Z Rheumatol 2000;59(Suppl 1):1-9.
54. Mosekilde L. Normal age-related changes in bone mass, structure, and strength - consequences of the remodeling process. Dan Med Bull 1993;40:65-83.
55. Chan GK, Duque G. Age-related bone loss: Old bone, new facts. Gerontology 2002;48:62-71.
56. Castillo C. Efecto de la administración de GH, estrógenos y melatonina sobre el proceso de envejecimiento. PhD Thesis Medical School, Complutense University, Madrid, Spain, 2005.
57. Iida H, Fukuda S. Age-related changes in bone mineral density, cross-sectional area and strength at different skeletal sites in male rats. J Vet Med Sci 2002;64:29-34.
58. Wang L, Banu J, McMahan CA, Kalu DN. Male rodent model of age-related bone loss in men. Bone 2001;29:141-148.
59. Su JL, Yang CY, Zhao M, Kuo ML. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem 2007;282:19385-19398.
60. Abed E, Couchourel D, Delalandre A, Duval N, Pelletier JP, Martel-Pelletier J, Lajeunesse D. Low sirtuin-1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/beta-catenin activity. Bone 2014;59:28-36.
61. Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone 2014;5.